Science, medicine, and the future: Microbubble contrast agents: A new era in ultrasound

British Medical Journal

Volumn 322, Issue 7296, 2001, Pages 1222-1225

  Blomley, Martin J K ^a   Cooke, Jennifer C ^b   Unger, Evan C ^c   Monaghan, Mark J ^b   Cosgrove, David O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; MICROSPHERE;

DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; IONIZING RADIATION; LASER; LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; ULTRASOUND; DRUG DELIVERY SYSTEM; ECHOGRAPHY; HUMAN; KIDNEY; LIVER CELL CARCINOMA; LIVER TUMOR; METHODOLOGY; VESICOURETERAL REFLUX;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; ECHOCARDIOGRAPHY; HUMANS; KIDNEY; LIVER NEOPLASMS; MICROSPHERES; ULTRASONOGRAPHY; VESICO-URETERAL REFLUX;

EID: 0035912617     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.322.7296.1222     Document Type: Review

References (30)

1. 1 Nanda NC,Carstensen C.Echo-enhancing agents: Safety. In Nanda NC, Schlief R, Goldberg BB, eds. Advances in Echo Imaging Using Contrast Enhancers. Dordrecht: Kluwer, 1997:115-31.
2. 2 Albrecht T, Urbank A, Mahler M, Bauer A, Dore CJ, Blomley MJ, et al. Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: preliminary experience. Radiology 1998;207:339-47.
3. 3 Ries F, Honisch C, Lambertz M, Schlief R. A transpulmonary contrast medium enhances the transcranial Doppler signal in humans. Stroke 1993;24:1903-9.
4. 4 Cosgrove D. Why do we need contrast agents for ultrasound? Clin Radiol 1996;51(suppl 1):1-4.
5. 5 Darge K, Troeger J, Duetting T, Zieger B, Rohrschneider W, Moehring K, et al. Reflux in young patients: comparison of voiding US of the bladder and retrovesical space with echo enhancement versus voiding cystourethrography for diagnosis. Radiology 1999;210:201-7.
6. 6 Strandell A, Bourne T, Bergh C, Granberg S, Asztely M, Thorburn J. The assessment of endometrial pathology and tubal patency: a comparison between the use of ultrasonography and X-ray hysterosalpingography for the investigation of infertility patients. Ultrasound Obstet Gynecol 1999;14:200-4.
7. 7 Blomley MJ, Albrecht T, Cosgrove DO, Eckersley RJ, Butler-Barnes J, Jayaram V, et al. Stimulated acoustic emission to image a late liver and spleen-specific phase of Levovist in normal volunteers and patients with and without liver disease. Ultrasound Med Biol 1999;25:1341-52.
8. 8 Forsberg F, Goldberg BB, Liu JB, Merton DA, Rawool NM, Shi WT. Tissue-specific US contrast agent for evaluation of hepatic and splenic parenchyma. Radiology 1999;210:125-32.
9. 9 Harvey CJ, Blomley MJ, Eckersley RJ, Heckemann RA, Butler-Barnes J, Cosgrove DO. Pulse-inversion mode imaging of liver specific microbubbles: improved detection of subcentimetre metastases. Lancet 2000; 355:807-8.
10. 10 Blomley MJ, Albrecht T, Cosgrove DO, Patel N, Jayaram V, Butler-Barnes J, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology 1999;210:409-16.
11. 11 Harvey CJ, Blomley MJK, Eckersley RJ, Heckemann RA, Butler-Barnes J, Cosgrove DO. Improved detection of hepatic malignancies using pulse inversion mode of the ultrasound contrast agent Levovist (SH U 508A): early experience. Radiology (in press).
12. 12 Albrecht T, Hoffmann CW, Schmitz SA, Schettler S, Overberg A, Germer CT, et al. Phase inversion sonography during the liver-specific phase of Levovist: improved detection of liver metastases. AJR Am J Roentgenol (in press).
13. 13 Blomley MJK, Albrecht T, Wilson SR, Burns PN, Lafortune M, Leen E, et al. Improved detection of metastatic liver lesions using pulse inversion harmonic imaging with Levovist: a multicenter study [abstract]. Radiology 1999;213(P):1685.
14. 14 Kim TK, Choi BI, Han JK, Hong HS, Park SH, Moon SG. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology 2000;216:411-7.
15. 15 Blomley MJK, Sidhu PS, Cosgrove DO, Albrecht T, Harvey CJ, Heckemann RA, et al. Do different types of liver lesion differ in their uptake of the microbubble SHU508 in its late liver phase: early experience. Radiology (in press).
16. 16 Albrecht T, Blomley MJK, Cosgrove DO. Non-invasive diagnosis of hepatic cirrhosis by transit time analysis of an ultrasound contrast agent. Lancet 1999;53:1579-83.
17. 17 Blomley MJ, Albrecht T, Cosgrove DO, Jayaram V, Eckersley RJ, Patel N, et al. Liver vascular transit time analyzed with dynamic hepatic venography with bolus injections of an US contrast agent: early experience in seven patients with metastases. Radiology 1998;209:862-6.
18. 18 Mulvagh SL, DeMaria AN, Feinstem SB, Burns PN, Kaul S, Miller JG, et al. Contrast echocardiography: current and future applications. J Am Soc Echocardiogr 2000;13:331-42.
19. 19 Cohen JL, Cheirif J, Segar DS, Gillam LD, Gottdiener JS, Hausnerova E, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III multicentre trial. J Am Coll Cardiol 1998;32:746-52.
20. 20 Cheng S-C, Dy TC, Feinstein SB. Contrast echocardiography: review and future directions. Am J Cardiol 1998;81(12A):41-8G.
21. 21 Cwajg J, Xie F, O'Leary E, Kricsfeld D, Dittrich H, Porter TR. Detection of angiographically significant coronary artery disease with accelerated intermittent imaging after intravenous administration of ultrasound contrast material. Am Heart J 2000;139:675-83.
22. 22 Czitrom D, Karila-Cohen D, Brochet E, Juliard JM, Faraggi M, Aumont M-C, et al. Acute assessment of microvascular perfusion patterns by myocardial contrast echocardiography during myocardial infarction: relation to timing and extent of functional recovery. Heart 1999;81:12-6.
23. 23 Burns PN, Becher H. Method for quantitative analysis. In: Handbook of contrast echocardiography. Frankfurt: Springer Verlag, 2000:154-69.
24. 24 Miller MW. Gene transfection and drug delivery. Ultrasound Med Biol 2000;26(suppl 1):S59-62.
25. 25 Russell SJ. Science, medicine, and the future: gene therapy. BMJ 1997;315:1289-92.
26. 26 Apfel RE, Holland CK. Gauging the likelihood of cavitation from short-pulse, low-duty cycle diagnostic ultrasound. Ultrasound Med Biol 1991;17:179-85.
27. 27 Porter TR, Iverson PL, Li S, Xia F. Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. J Ultrason Med 1996;15:577-84.
28. 28 Shohet RV, Chen S, Zhou Y-T, Wang Z, Meidell RS, Unger RH, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000;101:2554-6.
29. 29 Price RJ, Skyba DM, Kaul S, Skalak TC. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation 1998;98:1264-7.
30. 30 Wu Y, Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G, et al. Binding and lysing of blood clots using. MRX-408. Invest Radiol 1998;33;880-5.